Breaking News Instant updates and real-time market news.

MYL

Mylan

$38.15

-0.5 (-1.29%)

, VRX

Valeant

$13.46

-0.0103 (-0.08%)

10:20
05/19/17
05/19
10:20
05/19/17
10:20

USPTO sides with Mylan in challenge of Salix patent

The USPTO's Patent Trial and Appeal Board determined that claims 1 and 16 of the 8,865,688 patent owned by Dr. Falk Pharma GmbH are unpatentable. The patent relates to Salix Pharmaceuticals' Ulcerative Colitis treatment. Salix is owned by Valeant (VRX). The inter partes review of the patent was instituted following a challenge made by Mylan Pharmaceuticals (MYL).

MYL

Mylan

$38.15

-0.5 (-1.29%)

VRX

Valeant

$13.46

-0.0103 (-0.08%)

  • 19

    May

  • 22

    May

  • 06

    Jun

  • 24

    Aug

  • 03

    Sep

  • 09

    Oct

MYL Mylan
$38.15

-0.5 (-1.29%)

05/10/17
WELS
05/10/17
NO CHANGE
Target $40
WELS
Market Perform
Mylan deals masking 'weak' organic sales, says Wells Fargo
Wells Fargo analyst David Maris believes Mylan's deals are masking the company's contracting organic growth. When excluding deals, Mylan's total third party sales declined approximately 4% in Q1, with North American Sales down 11%, Europe down 1% and Rest of World up 11%, Maris tells investors in a post-earnings research note. He believes Mylan this morning reported an essentially in-line quarter on earnings, but that organic sales were "weak," particularly in North America. Maris has a Market Perform rating on Mylan with a $40 price target.
05/01/17
BMOC
05/01/17
INITIATION
Target $50
BMOC
Outperform
Mylan initiated with an Outperform at BMO Capital
BMO Capital analyst GaryNachman started Mylan with an Outperform rating and $50 price target. The company is one of the best positioned to navigate through the challenging generic trends over the longer term, the analyst argues.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
04/11/17
WELS
04/11/17
NO CHANGE
WELS
Market Perform
Wells unsure of risk to Mylan from FDA warning letter
Wells Fargo analyst David Maris says he does not know what products, if any, are manufactured at Mylan's India-based plant that received the warning letter from the FDA. As such, the letter may have little or no immediate commercial risk, Maris tells investors in an intraday research note. The analyst questions whether the FDA will stop letting drugs from this facility into the U.S. He adds that to him, "nothing is more critical for a brand or generic drug company than being able to ensure that its products are safe and effective." Maris keeps a Market Perform rating on Mylan.
VRX Valeant
$13.46

-0.0103 (-0.08%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.

TODAY'S FREE FLY STORIES

MRK

Merck

$63.73

-0.02 (-0.03%)

12:07
10/20/17
10/20
12:07
10/20/17
12:07
Periodicals
Merck to cut 1,800 jobs in sales reorganization, FiercePharma reports »

Merck plans to cut 1,800…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

AAPL

Apple

$155.98

-3.78 (-2.37%)

12:05
10/20/17
10/20
12:05
10/20/17
12:05
Periodicals
Apple's Ahrendts: Company will not upsell customers to iPhone X, CNBC says »

Apple's senior vice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

HAL

Halliburton

$43.45

0.03 (0.07%)

, VFC

VF Corp.

$66.70

1.35 (2.07%)

12:02
10/20/17
10/20
12:02
10/20/17
12:02
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$43.45

0.03 (0.07%)

VFC

VF Corp.

$66.70

1.35 (2.07%)

STT

State Street

$98.81

1.33 (1.36%)

STX

Seagate

$34.34

0.08 (0.23%)

SALT

Scorpio Bulkers

$8.15

0.4 (5.16%)

LOGI

Logitech

$36.61

-0.19 (-0.52%)

ITW

Illinois Tool Works

$153.94

0.46 (0.30%)

KMB

Kimberly-Clark

$113.03

-2.52 (-2.18%)

HAS

Hasbro

$96.67

-0.05 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

AVP

Avon Products

$2.28

0.015 (0.66%)

12:00
10/20/17
10/20
12:00
10/20/17
12:00
Options
Avon attracts call buying as shares edge off 52-week lows »

Avon attracts call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

12:00
10/20/17
10/20
12:00
10/20/17
12:00
General news
Treasury Option Action: heavy put volumes »

Treasury Option Action:…

RCII

Rent-A-Center

$10.64

0.11 (1.04%)

11:55
10/20/17
10/20
11:55
10/20/17
11:55
Options
Rent A Center put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

11:50
10/20/17
10/20
11:50
10/20/17
11:50
General news
NY Fed GDP forecasts trimmed: »

NY Fed GDP forecasts…

CTL

CenturyLink

$18.82

0.33 (1.78%)

11:40
10/20/17
10/20
11:40
10/20/17
11:40
Options
Serious call buying in CenturyLink »

Serious call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$174.56

-1.47 (-0.84%)

11:39
10/20/17
10/20
11:39
10/20/17
11:39
Periodicals
New Facebook feature Sets to rival Pinterest, TechCrunch reports »

A new Facebook feature…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

SHW

Sherwin-Williams

$388.13

0.5634 (0.15%)

11:33
10/20/17
10/20
11:33
10/20/17
11:33
Periodicals
Clearfield's Hilal pitches Sherwin-Williams as long idea, Bloomberg says »

Clearfield Capital's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

THFF

First Financial

$48.00

-0.05 (-0.10%)

11:30
10/20/17
10/20
11:30
10/20/17
11:30
Hot Stocks
First Financial declares special dividend of $1.50 per share »

The directors of First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$125.31

0.22 (0.18%)

11:30
10/20/17
10/20
11:30
10/20/17
11:30
Options
iShares Longer-term Bond ETF with notable put activity as shares fall »

iShares Longer-term Bond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$15.36

0.11 (0.72%)

11:21
10/20/17
10/20
11:21
10/20/17
11:21
Periodicals
Snap makes more employee cuts, plans to slow hiring in 2018, BI reports »

Snap has laid off 18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

  • 08

    Nov

  • 15

    Nov

S

Sprint

$7.00

-0.075 (-1.06%)

11:20
10/20/17
10/20
11:20
10/20/17
11:20
Options
Defensive option play opened in Sprint »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 16

    May

11:20
10/20/17
10/20
11:20
10/20/17
11:20
General news
Treasury Action: 3-year note is special in repo and fails rose to record highs »

Treasury Action: 3-year…

HNHPF

Hon Hai Precision

$7.28

-0.21 (-2.80%)

, AAPL

Apple

$155.98

-3.78 (-2.37%)

11:19
10/20/17
10/20
11:19
10/20/17
11:19
Periodicals
Foxconn chairman, Apple CEO intend to meet in Taiwan this month, Nikkei says »

Foxconn (HNHPF) chairman…

HNHPF

Hon Hai Precision

$7.28

-0.21 (-2.80%)

AAPL

Apple

$155.98

-3.78 (-2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

FDC

First Data

$18.96

0.505 (2.74%)

11:18
10/20/17
10/20
11:18
10/20/17
11:18
Upgrade
First Data rating change  »

Follow-up: First Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

$NSD

NASDAQ Market Internals

11:17
10/20/17
10/20
11:17
10/20/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
10/20/17
10/20
11:16
10/20/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBDRY

Iberdrola

$31.72

0.165 (0.52%)

, SIEGY

Siemens

$69.58

-0.295 (-0.42%)

11:11
10/20/17
10/20
11:11
10/20/17
11:11
Periodicals
Iberdrola calls for change at Siemens Gamesa after profit warning, Reuters says »

Iberdrola (IBDRY) has…

IBDRY

Iberdrola

$31.72

0.165 (0.52%)

SIEGY

Siemens

$69.58

-0.295 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

11:11
10/20/17
10/20
11:11
10/20/17
11:11
Syndicate
Breaking Syndicate news story on Sea Limited »

Sea Limited opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SE

Sea Limited

11:10
10/20/17
10/20
11:10
10/20/17
11:10
Syndicate
Breaking Syndicate news story on Sea Limited »

Sea Limited indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

XLF

Financial Select Sector

$26.55

0.22 (0.84%)

11:10
10/20/17
10/20
11:10
10/20/17
11:10
Options
SPDR Financial calls outpace puts 13:1 as shares reach multi-year highs »

SPDR Financial calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REDU

RISE Education Cayman

11:03
10/20/17
10/20
11:03
10/20/17
11:03
Syndicate
Breaking Syndicate news story on RISE Education Cayman »

RISE Education Cayman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AEG

AEGON

$5.84

-0.06 (-1.02%)

11:00
10/20/17
10/20
11:00
10/20/17
11:00
Periodicals
ASR rebuffs Aegon takeover approach, Reuters says »

Aegon had approached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.